Tagworks has several academic and commercial partnerships focused on developing and applying the In Vivo Chemistry platform.

We engage in collaborations with the biopharmaceutical industry on preclinical imaging and companion diagnostics for therapeutic antibody pipelines.

Tagworks is also open to strategic collaborations on pretargeted radioimmunotherapy and Antibody-Drug Conjugates, based on internal programs and/or third party constructs, addressing unmet clinical needs.

Contact us at to discuss the possibilities.

Furthermore, Tagworks is supported by several grants, provided by the European Union, the USA National Institutes of Health, and the USA Department of Defense.